A Type 1 diabetes genetic risk score can identify patients with glutamic acid decarboxylase (GAD) antibody-positive Type 2 diabetes with and without rapid progression to insulin therapy

A. L. Grubb, L. A. Donnelly, R. C. Slieker, T. J. McDonald, F. Rutters, L. M. 't Hart, E. R. Pearson, A. T. Hattersley, B. M. Shields, A. G. Jones, R. A. Oram, M. N. Weedon

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
Pages (from-to)204-204
JournalDiabetic Medicine
Volume35
Publication statusPublished - Mar 2018

Cite this

Grubb, A. L., Donnelly, L. A., Slieker, R. C., McDonald, T. J., Rutters, F., 't Hart, L. M., Pearson, E. R., Hattersley, A. T., Shields, B. M., Jones, A. G., Oram, R. A., & Weedon, M. N. (2018). A Type 1 diabetes genetic risk score can identify patients with glutamic acid decarboxylase (GAD) antibody-positive Type 2 diabetes with and without rapid progression to insulin therapy. Diabetic Medicine, 35, 204-204.